Short-term treatment with a peroxisome proliferator-activated receptor α agonist influences plasma one-carbon metabolites and B-vitamin status in rats

Vegard Lysne; Bodil Bjørndal; Mari Lausund Grinna; Øivind Midttun; Per Magne Ueland; Rolf Kristian Berge; Jutta Dierkes; Ottar Nygård; Elin Strand

doi:10.1371/journal.pone.0226069

. 2019 Dec 5;14(12):e0226069. doi: 10.1371/journal.pone.0226069

Short-term treatment with a peroxisome proliferator-activated receptor α agonist influences plasma one-carbon metabolites and B-vitamin status in rats

Vegard Lysne ^1,^*, Bodil Bjørndal ², Mari Lausund Grinna ², Øivind Midttun ³, Per Magne Ueland ^2,³, Rolf Kristian Berge ^2,⁴, Jutta Dierkes ^5,^6,⁷, Ottar Nygård ^1,^4,⁶, Elin Strand ²

Editor: Nick Ashton⁸

PMCID: PMC6894826 PMID: 31805132

Abstract

Introduction

Peroxisome proliferator-activated receptors (PPARs) have been suggested to be involved in the regulation of one-carbon metabolism. Previously we have reported effects on plasma concentrations of metabolites along these pathways as well as markers of B-vitamin status in rats following treatment with a pan-PPAR agonist. Here we aimed to investigate the effect on these metabolites after specific activation of the PPARα and PPARγ subtypes.

Methods

For a period of 12 days, Male Wistar rats (n = 20) were randomly allocated to receive treatment with the PPARα agonist WY-14.643 (n = 6), the PPARγ agonist rosiglitazone (n = 6) or placebo (n = 8). The animals were sacrificed under fasting conditions, and plasma concentration of metabolites were determined. Group differences were assessed by one-way ANOVA, and planned comparisons were performed for both active treatment groups towards the control group.

Results

Treatment with a PPARα agonist was associated with increased plasma concentrations of most biomarkers, with the most pronounced differences observed for betaine, dimethylglycine, glycine, nicotinamide, methylnicotinamide, pyridoxal and methylmalonic acid. Lower levels were observed for flavin mononucleotide. Fewer associations were observed after treatment with a PPARγ agonist, and the most notable was increased plasma serine.

Conclusion

Treatment with a PPARα agonist influenced plasma concentration of one-carbon metabolites and markers of B-vitamin status. This confirms previous findings, suggesting specific involvement of PPARα in the regulation of these metabolic pathways as well as the status of closely related B-vitamins.

Introduction

The choline oxidation pathway consists of the metabolic reactions converting choline, originating from endogenous synthesis or from the diet, to glycine via the intermediate metabolites betaine, dimethylglycine (DMG) and sarcosine. Glycine may also be reversibly synthesized from serine via serine-hydroxymethyltransferase. The choline oxidation pathway is closely related to the homocysteine-methionine cycle, through the enzyme betaine-homocysteine methyl transferase (BHMT) [1]. In this reaction a methyl group is transferred from betaine to homocysteine, producing methionine and DMG. The other homocysteine remethylation pathway is catalyzed by methionine synthase (MS), where the methyl group is transferred from 5’-methyltetrahydrofolate (mTHF) via the MS bound cofactor methylcobalamin (vitamin B12) forming methionine. Alternatively to remethylation, homocysteine may be irreversibly catabolized through the transsulfuration pathway, by the enzymes cystathionine-β-synthase and cystathionine-γ-lyase (Fig 1) [2]. Plasma and urinary concentration of metabolites in this pathway, including choline [3–5], betaine [5–7], DMG [8–10], sarcosine [11, 12], glycine and serine [13–15], have been linked to risk of major lifestyle diseases such as diabetes, cancer and cardiovascular disease.

Fig 1 — The numbers indicate enzymes, and the black boxes indicate enzymes of which gene expression have been previously shown to be down regulated by PPARα activation. The figure indicates where the enzymatic reactions occur (within/outside mitocondria). DMG indicates dimethylglycine; Hcy, homocysteine; Met, methionine; mTHF, 5’-methyltetrahydrofolate and THF, tetrahydrofolate.

Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors involved in the regulation of a variety of metabolic functions, including different aspects of energy metabolism [16, 17]. Recent studies in animals have implicated PPARs, in particular the PPARα subtype, in the regulation of one-carbon metabolism pathways. Down regulation of the genes encoding DMG dehydrogenase (DMGDH), sarcosine dehydrogenase (SARDH) and glycine-N-methyltransferase (GNMT) of the choline oxidation pathway [18], as well as both enzymes of the transsulfuration pathway [18, 19], have been observed after PPARα activation in rats. Down regulation on the protein level of BHMT, DMGDH, SARDH and GNMT have also been observed in rats and mice [20, 21].

Treatment of humans with fibrates, which are PPARα agonists, have consistently been associated with increased plasma total homocysteine (tHcy) [22, 23], and also decreased plasma betaine concentrations [24, 25] and increased urinary output of choline, betaine and DMG [24–27]. In animals, PPARα activation has been associated with increased plasma DMG [28] as well as increased glycine and serine [18, 28–31]. PPARα activation in animals have also been linked to altered status of several B-vitamins, such as increased plasma concentrations of riboflavin [31], nicotinamide (NAM) and N¹-methylnicotinamide (mNAM) [28, 31], the vitamin B6 indices pyridoxal (PL) and pyridoxal-5’-phosphate (PLP) [28] and the functional marker of cobalamin deficiency, methylmalonic acid (MMA) [28], and reduced plasma folate [28]. Reduced folate has also been reported in humans by some [32], but not all [33]. Increased urinary output of NAM and mNAM have been consistently reported in rodents [18, 28, 31, 34, 35].

In a previous study of male Wistar rats [28], we demonstrated that long-term treatment with the pan-PPAR agonist tetradecylthioacetic acid (TTA) was associated with alteration in the plasma concentration of several metabolites along the choline oxidation pathway as well as markers of B-vitamin status. However, as TTA is a pan-PPAR agonist we could not conclude whether this was a result of PPARα-activation, activation of other PPAR subtypes or PPAR-independent effects of the TTA treatment.

In the current study, we aim to extend on our previous findings and clarify the role of PPAR-activation on plasma concentration of one-carbon metabolites, as well as the status of related B-vitamins. We measured these metabolites in plasma from animals treated with specific PPARα and PPARγ agonists.

Materials and methods

Animals and study design

The current study is a substudy of an experiment aiming to explore the role of short-term activation of PPARs on lipid and fatty acid composition in liver and heart, and the experimental setup has been described in detail elsewhere [36].

Briefly, a total of 20 male Wistar rats (Taconic Europe A/S, Ry, Denmark), aged 8 weeks and with a body weight of 200-225g, were randomized into three groups: 1) Control (n = 8), 2) PPARα agonist (PPARα, n = 6); and 3) PPARγ agonist (PPARγ, n = 6). During 12 days of intervention, the animals received standard low-fat chow diet, and the daily treatments were given as 300 μl of muffin dough as vehicle, containing the active agent or placebo. The control group received pure vehicle, the PPARα group received 20 mg/kg/day of WY-14.643 (Tocris Bioscience, Bristol, UK) and the PPARγ group received 10 mg/kg/day Rosiglitazone (Sigma-Aldrich, St. Louis, MO). The muffin dough vehicle contained eggs, sugar, gluten free flour, vanilla sugar, milk and butter.

The animals were housed 2–3 per cage, and had free access to chow diet and tap water during the full study period. Prior to the study, the animals were habituated to the cage conditions and experimental handling, and introduced to the muffin dough vehicle. Animals in the same cage belonged to the same experimental group, but were taken out of the cages to receive treatment to ensure equal dosing. Cage placement, sequence of animal handling and termination were block randomized. After 12 days, the animals were sacrificed under fasting conditions, by cardiac puncture and exsanguination after receiving anesthesia with 2% isoflurane (Schering-Plough, Kent, UK).

Feed intake was estimated by weighing the food provided to the cages, as well as residual feed. During the intervention, feed intake and total weight gain was somewhat higher in animals treated with PPARγ-agoinst, but liver weight was increased in rats treated with PPARα-agonist. In the PPARα-group, hepatic expression of PPARα was 61% higher, and the expression of known PPARα target genes such as Acox1 (9-fold increase), Cd36 (9-fold increase), LPL (6-fold increase) and Hmgcs2 (2-fold increase) were affected by treatment with PPARα-agonist, demonstrating activation of PPARα in the liver [36]. Further, adipose tissue expression of known PPARγ target genes, such as Fatp1 (3-fold increase) and Fabp4 (0.5-fold increase) were affected by treatment with PPARγ agonist, demonstrating activation of PPARγ [36].

Ethics statement

The animal experiments complied with the Guidelines for the Care and Use of Experimental Animal use and the study protocols were approved by the national animal research authority (FOTS, ID number 2014/6187).

Biochemical analyses

Quantification of plasma metabolites were performed at Bevital A/S (Bevital, Bergen, Norway, www.bevital.no), using gas- or liquid chromatography coupled with tandem mass spectrometry for all metabolites except cobalamin which was analyzed by microbiological assay [37–40]. For the purpose of this targeted metabolomics approach, the metabolites of interest included the metabolites of the methionine-homocysteine cycle and the transsulfuration pathway (methionine, tHcy, cystathionine and cysteine), the choline oxidation pathway (choline, betaine, DMG, glycine and serine), as well as markers of related B-vitamins (Flavin mononucleotide [FMN], NAM, mNAM, Nicotinic acid [NA], PL, PLP, 4-pyridoxic acid (PA), the PAr-index (Par, calculated as the ratio of 4-pyridoxic acid divided by the sum of pyridoxal 5'-phosphate plus pyridoxal), mTHF, cobalamin and MMA).

Statistical analyses and presentation of data

The animals were housed 2–3 per cage, but as the rats were taken out of the cages to receive the intervention, the individual rat was regarded as the experimental unit of analysis. Plasma metabolite concentrations were log-transformed, and the data are presented as geometric means (geometric standard deviation, gSD). The groups were compared by one-way ANOVA, and the proportion of variance explained by the experimental groups were assessed by calculating the η². The assumption of equal variances was assessed with Levene’s test and visually by plotting the residuals. Within-group normality was visualized by Q-Q plots of the residuals. Planned comparisons towards the control group were performed for the two intervention groups. Standardized mean difference (SMD; 95% confidence interval) were calculated and plotted to illustrate the differences from the control group. For effect sizes, Cohen’s cutoff of η² > 35% was considered a large proportion of explained variance [41], and SMD > 1 were considered a large effect size. All individual data points are presented in S1 Fig. To evaluate potential cage effects, data was also plotted treating the cages as the experimental unit (n = 2–3 per group, S2 Fig).

As no new experiments were performed for this investigation, no formal power calculation was conducted. However, the current sample size was considered sufficient for replication of the most pronounces differences previously reported (SMD > 3) [28]. At a conventional cutoff for statistical significance at p < 0.05 the current sample sizes would yield 71% power to detect a large variance explained (η² > 35%), and 80% power of detecting between-group differences of SMD > 1.65.

Statistical analyses were performed using R software version 3.5.1 [42], and the packages within the tidyverse (dplyr, broom, purrr, magrittr, rlang) and forestplot.

Results

The plasma concentration of metabolites and the SMD (95% CI) for the intervention groups versus the control group are given in Fig 2. Overall, more and larger differences were observed after treatment with PPARα agonist compared to PPARγ agonist.

Methionine (η² = 52%, p = 0.009), homocysteine (η² = 48%, p = 0.016) and cystathionine (η² = 39%, p = 0.048) were different between the groups. Planned comparisons showed that methionine (SMD = -1.5), homocysteine (SMD = -1.4) and cystathionine (SMD = -0.88) were lower after treatment with PPARγ agonist, while all metabolites were higher after treatment with PPARα agonist(SMD = 1.0, 1.0 and 0.9, respectively).

In the choline oxidation pathway, group differences were observed for betaine (η² = 68%, p < 0.001), DMG (η² = 68%, p < 0.001), glycine (η² = 81%, p < 0.001), and serine (η² = 60%, p < 0.001). The planned comparisons demonstrated higher concentrations of betaine (SMD = 2.7), DMG (SMD = 3.4), glycine (SMD = 4.4) and serine (SMD = 2.4) in the PPARα group. Lower plasma choline (SMD = -1.5), and higher serine (d = 1.9) was observed in the PPARγ group.

FMN, but not riboflavin, was different between the groups (η² = 65%, p < 0.001), and the planned comparisons revealed this to be due to lower concentrations in the PPARα group (SMD = -2.4). NAM and mNAM were different between groups (both η² > 90%, p < 0.001), and this was entirely explained by higher levels after treatment with PPARα agonist(SMD = 6.6 and 5.9, respectively). The same pattern was seen for the two vitamin B6 forms PL and PLP (η² = 74% and 48%, both p < 0.001), where higher concentrations in the PPARα agonist group explained the difference (SMD = 3.9 and 2.0, respectively). A between-group difference was observed for cobalamin (η² = 43%, p = 0.03) and its functional marker MMA (η² = 73%, p < 0.001). PPARα agonistic treatment was associated with lower plasma cobalamin (SMD = -1.8) and higher MMA (SMD = 3.0).

Discussion

This short-term study of one-carbon metabolites and B-vitamins in male Wistar rats treated with PPAR agonists demonstrated pronounced effects of PPARα agonist on the plasma concentration of metabolites of the choline oxidation pathway and markers of B-vitamin status. The largest differences were seen for plasma betaine, DMG, glycine, NAM, mNAM, PL and MMA, which were all higher, and FMN which was lower in the PPARα group. The current findings confirm our previous observations on effects of the pan-PPAR agonist TTA [28], and suggest that these biomarker alterations are due to PPARα activation.

In the PPARα group, higher plasma concentrations were observed for several metabolites of the choline oxidation pathway, including betaine, DMG, glycine and serine, with a majority of the observed variation in these variables (η² = 60–81%) being explained by the model. The increased concentrations of these metabolites may indicate increased flux through the choline oxidation pathway. Although plasma mTHF did not differ between groups, the lower cobalamin and higher MMA levels observed in the PPARα group may indicate lower cobalamin availability. This could reduce the activity of the MS-mediated homocysteine remethylation pathway, causing a compensatory increase in BHMT flux. PPARα-induced down regulation of DMGDH and SARDH may cause accumulation of their upstream metabolites, DMG and sarcosine. Unfortunately, we were not able to determine plasma concentrations of sarcosine, due to analytical interference from the EDTA in the tubes used for blood sampling. Both DMGDH and SARDH are flavoproteins and lower concentrations of FMN may indicate lower cofactor availability, potentially contributing to reduced enzyme activities.

Compared to control, plasma glycine and serine concentrations were much higher in the PPARα group, which have been consistently found in other animal studies [18, 28–31, 43]. Ericsson et al demonstrated that the increased plasma glycine levels were primarily due to increased entry into plasma, possibly reflecting increased de novo synthesis [29]. In addition to the choline oxidation pathway, glycine may originate from carnitine synthesis, threonine catabolism or from glycolysis via serine [44, 45]. Increased carnitine synthesis has been demonstrated after PPARα activation [46], in line with the known increases in β-oxidation and lowering of triglycerides. Hence, increased carnitine synthesis following PPARα activation is a likely contributor to increased plasma glycine. However, circulating concentration of carnitines were lower after PPARα agonistic treatment in the current experiment [36]. PPARα is known to increase lipid oxidation and sparing glucose [47], hence, glucose metabolism is not a likely contributor to the observed increases in plasma glycine and serine in the PPARα group. Higher plasma serine may be related to interconversion of excess glycine through serine-hydroxymethyltransferase. Upstream accumulation of glycine and serine following PPARα-induced down-regulation of GNMT is another potentially contributing factor [18]. Higher plasma serine observed after treatment with PPARγ agonist may be related to increased glycolysis, as PPARγ activation is known to increase insulin sensitivity, facilitating increased glucose utilization, as well as directly influence hepatic glucose uptake [48].

As in our previous report we observe lower plasma levels of the vitamin B2 metabolite FMN after treatment with PPARα agonist [28]. This could reflect reduced formation of FMN from riboflavin through riboflavin kinase or increased metabolism of FMN to flavin adenine dinucleotide (FAD) by FAD synthase. Notably, FAD acts as a product inhibitor of its own synthesis [49]. Hence, increased FAD utilization may increase FAD synthesis, and thus reduce FMN and riboflavin levels. FAD acts as an electron acceptor in the first step of β-oxidation, and although speculative, this may suggest that PPARα induced increases in hepatic fatty acid oxidation may drive the conversion from FMN to FAD, by product removal. Lower plasma riboflavin and FMN may thus reflect the altered cofactor requirements following PPARα induced changes in energy metabolism.

The largest response to intervention in the current study were the higher concentrations of plasma NAM and mNAM in the PPARα group, with an excess of 90% of the observed variation being explained by the model. We [28] and others [18, 28, 31, 34, 35, 50, 51] have previously observed a marked increase in B3 vitamers in plasma, urine and liver of rodents treated with PPARα agonists. Thus, these observations fits well with the existing literature. In addition to dietary consumption, NAM may be endogenously formed from the amino acid tryptophan through the kynurenine pathway [52]. Amino-carboxymuconate semialdehyde (ACMS), a downstream metabolite of this pathway, is either catabolized by the enzyme ACMS dehydrogenase or converted to quinolinic acid and metabolized further to NAM through quinolinic acid phosphoribosyltransferase (QAPRT). PPARα activation has been shown to down regulate ACMS dehydrogenase and up regulate QAPRT [53, 54], shifting the flux towards increased niacin synthesis from tryptophan. We believe this offers a mechanistic explanation of our observations, suggesting NAM and/or mNAM as potential biomarkers of PPARα activity. This has to be examined in future studies.

Similar to our previous findings [28], we observe higher concentrations of both circulating B6 vitamers PL and PLP in the PPARα group. Vitamin B6 status is inversely associated with inflammation [55], and PLP has been suggested as a scavenger of reactive oxidative species [56]. Hence, the increased plasma concentrations of PL and PLP may be related to the anti-inflammatory and anti-oxidative properties of PPARα activation [17]. Of interest, we observe larger increases in PL compared to PLP. One possible explanation may be increased conversion from PLP to PL, a reaction catalyzed by alkaline phosphatase [56]. Increased alkaline phosphatase mRNA has been demonstrated after PPARα activation in cell culture studies [57]. Additionally, the final step in the synthesis of PLP from its precursors pyridoxine-5’-phosphate and pyridoxamine-5’-phospate is catalyzed by pyridoxamine 5’-phosphate oxidase which is a FMN-dependent protein [56, 58], and lower FMN availability may contribute to reduced PLP synthesis via this route. This is also in line with observations that fibrate treatment does not change plasma PLP concentrations in humans [33].

We observed a large increase in plasma MMA after treatment with PPARα agonist, in accordance with what we previously reported after treatment with pan-PPAR agonist [28]. Although MMA is considered a functional biomarker of vitamin B12 deficiency, much of the variation in plasma MMA is not accounted for by vitamin B12 status, suggesting that B12 independent mechanisms might also be at play [59]. Of interest, Molloy et al identified a novel genetic variant in the metabolism of branched-chain amino acids (BCAA), explaining 9.9% of the variance of circulating MMA, independent of vitamin B12 status [60].

There are several possible ways PPARα activation may contribute to increased MMA; by increasing the availability of precursors, by interfering with intracellular vitamin B12 processing or by directly interfering with the methylmalonyl-CoA mutase reaction. The precursor of methylmalonyl-CoA is propionyl-CoA, resulting from catabolism of BCAA and odd-chained fatty acids. PPARα activation is well known to stimulate hepatic fatty acid oxidation [61] and has also been demonstrated to increase the catabolism of BCAA [62], suggesting an effect of PPARα activation on availability of MMA precursors.

A key step in the intracellular processing of cobalamin is the liberation of free cobalamin within the cell cytosol, a reaction involving by the MMACHC protein, and partitioning to the two cobalamin dependent proteins, facilitated by the MMADHC protein. MMACHC is a flavoprotein dependent on glutathione (GSH) for its function [63], and the availability of both GSH and FAD may be limited under conditions of increased PPARα activity. GSH production is directly related to the level of oxidative stress, and as much as half of the cysteine utilized for GSH production is derived from homocysteine through the transsulfuration pathway [64]. Anti-oxidative properties of PPARα agonists [17], combined with down regulation of both enzymes of the transsulfuration pathway [18, 19], may reduce GSH availability following PPARα activation. Further, mmachc and mmadhc are predicted PPAR target genes [65]. Hence, PPARα induced interference with intracellular processing of vitamin B12 and its availability as co-factor of methylmalonyl-CoA mutase, may contribute to increased MMA.

Strengths and limitations

The main strength of this study is the use of specific PPARα and PPARγ agonists, allowing for evaluation of the specific effects of PPAR subtypes. As animals residing in the same cage belonged to the same experimental group, the possibility of cage effects could not be completely excluded, although the animals were individually treated outside the cages. However, by plotting cage mean values instead of individual measurements, the same patterns emerged and within-group cage means were similar (S2 Fig) to the results obtained by using the individual animals. Hence, bias due to cage effects is not likely to have influenced our main conclusions. It has to be noted that the effect of PPAR agonists on one-carbon and B-vitamin metabolome was a secondary aim of this experiment. However, maximizing the information gained from the animals contributes to reducing the number of animals sacrificed, which is in line with the 3 R’s of animal research [66]. We did not measure PPARα and PPARγ activity or protein expression in this study, which may be considered a limitation. Measuring protein expression of PPARs would not necessarily add any information regarding their activity, since this involves several factors. However, activation of the PPARs with the agonists administered in this study has been thoroughly demonstrated in the literature, and increased expression of known PPARα and PPARγ target genes were observed in the current experiment [36]. Further, the discussion on potential mechanisms would benefit from information regarding the expression of genes along the pathways discussed. Unfortunately, as this information could not be obtained from the current experiment, the mechanistic discussion relies on effects previously reported in the literature. However, as previous publications have not provided complete information regarding effects on the metabolite level, the current data should be interpreted as complimentary to the existing literature.

Conclusion

In this study, short-term treatment with a specific PPARα, but not PPARγ, agonist influenced plasma concentrations of several one-carbon metabolites and markers of B-vitamin status, with the most pronounced findings being higher DMG, glycine, serine, NAM, mNAM, PL and MMA, and lower FMN. This targeted metabolomics approach adds to the current literature suggesting the involvement of PPARα in the regulation of these metabolic pathways, as well as the status of closely related B-vitamins.

Supporting information

S1 Arrive Checklist

(PDF)

Click here for additional data file.^{(1MB, pdf)}

S1 Fig. Individual metabolite concentrations with overlaying box plots.

Black dots represents the control group, red dots represents the PPARα group and blue dots represents the PPARγ group. DMG, dimethylglycine; FMN, Flavin mononucleotide; MMA, methylmalonic acid; mNAM, methylnicotinamide; mTHF, 5’-methyltetrahydrofolate; NA, nicotinic acid; NAM, nicotinamide; mNAM, N1-methylnicotinamide; PA, 4-pyridoxic acid; pABG, para-aminobenzoylglutamate; PAr, PA/(PLP+PL); PL, pyridoxal; PLP, pyridoxal 5’-phosphate.

(TIF)

Click here for additional data file.^{(2.7MB, tif)}

S2 Fig. Cage mean metabolite concentrations with overlaying box plots.

(TIF)

Click here for additional data file.^{(2.5MB, tif)}

S1 Dataset. Raw data on metabolite concentrations.

(XLSX)

Click here for additional data file.^{(12.5KB, xlsx)}

Acknowledgments

The authors would like to thank Kari Mortensen, Kari Williams, Randi Sandvik, Liv Kristine Øysæd, Svein Kruger, Marte Trollebø and Torunn Eide for their valuable technical assistance during the study. We also thank the staff at the Laboratory Animal Facility at the University of Bergen.

Abbreviations

ACMS: Aminocarboxymuconate semialdehyde
BCAA: Branched-chain amino acids
BHMT: Betaine-homocysteine methyltransferase
DMG: Dimethylglycine
DMGDH: Dimethylglycine dehydrogenase
FMN: Flavin mononucleotide
GNMT: Glycine-N-methyltransferase
gSD: Geometric standard deviation
GSH: Glutathione
MMA: Methylmalonic acid
mNAM: N¹-methylnicotinamide
MS: Methinine synthase
mTHF: 5’-methyltetrahydrofolate
NA: Nicotinic acid
NAM: Nicotinamide
PA: Pyridoxic acid
PAr: PAr-index
PL: Pyridoxal
PLP: Pyridoxal-5’-phosphate
PPAR: Peroxisome proliferator-activated receptor
QAPRT: Quinolinic acid phosphoribosyltransferase
SARDH: Sarcosine dehydrogenase
SMD: Standardized mean difference
TTA: Tetradecylthioacetic acid

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

Authors ØM and PMU are employed by BEVITAL A/S (www.bevital.no), who performed the biochemical analyses for this study. The funder provided support in the form of salaries for authors [ØM and PMU], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.

References

1.Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1(5):228–37. 10.1016/0955-2863(90)90070-2 [DOI] [PubMed] [Google Scholar]
2.Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217–46. 10.1146/annurev.nutr.19.1.217 [DOI] [PubMed] [Google Scholar]
3.Svingen GF, Schartum-Hansen H, Pedersen ER, Ueland PM, Tell GS, Mellgren G, et al. Prospective Associations of Systemic and Urinary Choline Metabolites with Incident Type 2 Diabetes. Clin Chem. 2016;62(5):755–65. 10.1373/clinchem.2015.250761 [DOI] [PubMed] [Google Scholar]
4.Schartum-Hansen H, Pedersen ER, Svingen GF, Ueland PM, Seifert R, Ebbing M, et al. Plasma choline, smoking, and long-term prognosis in patients with stable angina pectoris. European journal of preventive cardiology. 2014;22(5):606–14. 10.1177/2047487314524867 [DOI] [PubMed] [Google Scholar]
5.Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis. 2011;34(1):3–15. 10.1007/s10545-010-9088-4 [DOI] [PubMed] [Google Scholar]
6.Schartum-Hansen H, Ueland PM, Pedersen ER, Meyer K, Ebbing M, Bleie O, et al. Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients. PLoS One. 2013;8(8):e69454 10.1371/journal.pone.0069454 [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Lever M, George PM, Elmslie JL, Atkinson W, Slow S, Molyneux SL, et al. Betaine and secondary events in an acute coronary syndrome cohort. PLoS One. 2012;7(5):e37883 10.1371/journal.pone.0037883 [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Svingen GF, Schartum-Hansen H, Ueland PM, Pedersen ER, Seifert R, Ebbing M, et al. Elevated plasma dimethylglycine is a risk marker of mortality in patients with coronary heart disease. European journal of preventive cardiology. 2014;22(6):743–52. 10.1177/2047487314529351 [DOI] [PubMed] [Google Scholar]
9.Oyen J, Svingen GF, Gjesdal CG, Tell GS, Ueland PM, Lysne V, et al. Plasma dimethylglycine, nicotine exposure and risk of low bone mineral density and hip fracture: the Hordaland Health Study. Osteoporos Int. 2015;26(5):1573–83. 10.1007/s00198-015-3030-4 [DOI] [PubMed] [Google Scholar]
10.Svingen GF, Ueland PM, Pedersen EK, Schartum-Hansen H, Seifert R, Ebbing M, et al. Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol. 2013;33(8):2041–8. 10.1161/ATVBAHA.113.301714 [DOI] [PubMed] [Google Scholar]
11.Koutros S, Meyer TE, Fox SD, Issaq HJ, Veenstra TD, Huang WY, et al. Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis. 2013;34(10):2281–5. 10.1093/carcin/bgt176 [DOI] [PMC free article] [PubMed] [Google Scholar]
12.de Vogel S, Ulvik A, Meyer K, Ueland PM, Nygard O, Vollset SE, et al. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer—a large nested case-control study within the JANUS cohort in Norway. Int J Cancer. 2014;134(1):197–206. 10.1002/ijc.28347 [DOI] [PubMed] [Google Scholar]
13.Ding Y, Svingen GF, Pedersen ER, Gregory JF, Ueland PM, Tell GS, et al. Plasma Glycine and Risk of Acute Myocardial Infarction in Patients With Suspected Stable Angina Pectoris. J Am Heart Assoc. 2015;5(1):e002621 10.1161/JAHA.115.002621 [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13(8):572–83. 10.1038/nrc3557 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39(4):191–8. 10.1016/j.tibs.2014.02.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Rakhshandehroo M, Knoch B, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Contreras AV, Torres N, Tovar AR. PPAR-alpha as a key nutritional and environmental sensor for metabolic adaptation. Adv Nutr. 2013;4(4):439–52. 10.3945/an.113.003798 [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR, Oakes ND. Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. American journal of physiology Endocrinology and metabolism. 2007;292(4):E1157–65. 10.1152/ajpendo.00254.2006 [DOI] [PubMed] [Google Scholar]
19.Rogue A, Renaud MP, Claude N, Guillouzo A, Spire C. Comparative gene expression profiles induced by PPARgamma and PPARalpha/gamma agonists in rat hepatocytes. Toxicol Appl Pharmacol. 2011;254(1):18–31. 10.1016/j.taap.2011.04.005 [DOI] [PubMed] [Google Scholar]
20.Wrzesinski K, I RL, Kulej K, Sprenger RR, Bjorndal B, Christensen BJ, et al. Proteomics identifies molecular networks affected by tetradecylthioacetic acid and fish oil supplemented diets. J Proteomics. 2013;84:61–77. 10.1016/j.jprot.2013.03.027 [DOI] [PubMed] [Google Scholar]
21.Chu R, Lim H, Brumfield L, Liu H, Herring C, Ulintz P, et al. Protein profiling of mouse livers with peroxisome proliferator-activated receptor alpha activation. Mol Cell Biol. 2004;24(14):6288–97. 10.1128/MCB.24.14.6288-6297.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Ntaios G, Savopoulos C, Chatzopoulos S, Mikhailidis D, Hatzitolios A. Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis. 2011;214(1):11–9. 10.1016/j.atherosclerosis.2010.08.045 [DOI] [PubMed] [Google Scholar]
23.Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med. 2005;5(2):124–39. 10.1055/s-2005-872398 [DOI] [PubMed] [Google Scholar]
24.Lever M, McEntyre CJ, George PM, Slow S, Chambers ST, Foucher C. Fenofibrate causes elevation of betaine excretion but not excretion of other osmolytes by healthy adults. J Clin Lipidol. 2014;8(4):433–40. 10.1016/j.jacl.2014.04.001 [DOI] [PubMed] [Google Scholar]
25.Lever M, McEntyre CJ, George PM, Slow S, Elmslie JL, Lunt H, et al. Extreme urinary betaine losses in type 2 diabetes combined with bezafibrate treatment are associated with losses of dimethylglycine and choline but not with increased losses of other osmolytes. Cardiovasc Drugs Ther. 2014;28(5):459–68. 10.1007/s10557-014-6542-9 [DOI] [PubMed] [Google Scholar]
26.Lever M, George PM, Slow S, Elmslie JL, Scott RS, Richards AM, et al. Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc Drugs Ther. 2009;23(5):395–401. 10.1007/s10557-009-6188-1 [DOI] [PubMed] [Google Scholar]
27.Lever M, George PM, Atkinson W, Molyneux SL, Elmslie JL, Slow S, et al. Plasma lipids and betaine are related in an acute coronary syndrome cohort. PLoS One. 2011;6(7):e21666 10.1371/journal.pone.0021666 [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Lysne V, Strand E, Svingen GF, Bjorndal B, Pedersen ER, Midttun O, et al. Peroxisome Proliferator-Activated Receptor Activation is Associated with Altered Plasma One-Carbon Metabolites and B-Vitamin Status in Rats. Nutrients. 2016;8(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Ericsson A, Turner N, Hansson GI, Wallenius K, Oakes ND. Pharmacological PPARalpha activation markedly alters plasma turnover of the amino acids glycine, serine and arginine in the rat. PLoS One. 2014;9(12):e113328 10.1371/journal.pone.0113328 [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Lu Y, Boekschoten MV, Wopereis S, Muller M, Kersten S. Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice. Physiol Genomics. 2011;43(23):1307–18. 10.1152/physiolgenomics.00100.2011 [DOI] [PubMed] [Google Scholar]
31.Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol. 2009;37(4):521–35. 10.1177/0192623309336152 [DOI] [PubMed] [Google Scholar]
32.Mayer O Jr., Simon J, Holubec L, Pikner R, Subrt I. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur J Clin Pharmacol. 2003;59(5–6):367–71. 10.1007/s00228-003-0616-0 [DOI] [PubMed] [Google Scholar]
33.Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999;354(9174):219–20. 10.1016/S0140-6736(99)02153-4 [DOI] [PubMed] [Google Scholar]
34.Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ. Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol. 2007;21(9):2136–51. 10.1210/me.2007-0150 [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Delaney J, Hodson MP, Thakkar H, Connor SC, Sweatman BC, Kenny SP, et al. Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Arch Toxicol. 2005;79(4):208–23. 10.1007/s00204-004-0625-5 [DOI] [PubMed] [Google Scholar]
36.Strand E, Lysne V, Grinna ML, Bohov P, Svardal A, #xf8, et al. Short-Term Activation of Peroxisome Proliferator-Activated Receptors and Induces Tissue-Specific Effects on Lipid Metabolism and Fatty Acid Composition in Male Wistar Rats. PPAR Research. 2019;2019:12. [DOI] [PMC free article] [PubMed] [Google Scholar]
37.Midttun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009;23(9):1371–9. 10.1002/rcm.4013 [DOI] [PubMed] [Google Scholar]
38.Midttun O, Kvalheim G, Ueland PM. High-throughput, low-volume, multianalyte quantification of plasma metabolites related to one-carbon metabolism using HPLC-MS/MS. Anal Bioanal Chem. 2013;405(6):2009–17. 10.1007/s00216-012-6602-6 [DOI] [PubMed] [Google Scholar]
39.Kelleher BP, Broin SD. Microbiological assay for vitamin B12 performed in 96-well microtitre plates. J Clin Pathol. 1991;44(7):592–5. 10.1136/jcp.44.7.592 [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Midttun O, McCann A, Aarseth O, Krokeide M, Kvalheim G, Meyer K, et al. Combined Measurement of 6 Fat-Soluble Vitamins and 26 Water-Soluble Functional Vitamin Markers and Amino Acids in 50 muL of Serum or Plasma by High-Throughput Mass Spectrometry. Anal Chem. 2016;88(21):10427–36. 10.1021/acs.analchem.6b02325 [DOI] [PubMed] [Google Scholar]
41.Cohen J. A power primer. Psychol Bull. 1992;112(1):155–9. 10.1037//0033-2909.112.1.155 [DOI] [PubMed] [Google Scholar]
42.Team RC. R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing, Vienna, Austria; 2018. [Google Scholar]
43.Bjorndal B, Brattelid T, Strand E, Vigerust NF, Svingen GF, Svardal A, et al. Fish oil and the pan-PPAR agonist tetradecylthioacetic acid affect the amino acid and carnitine metabolism in rats. PLoS One. 2013;8(6):e66926 10.1371/journal.pone.0066926 [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Bremer J. Carnitine—metabolism and functions. Physiol Rev. 1983;63(4):1420–80. 10.1152/physrev.1983.63.4.1420 [DOI] [PubMed] [Google Scholar]
45.Wang W, Wu Z, Dai Z, Yang Y, Wang J, Wu G. Glycine metabolism in animals and humans: implications for nutrition and health. J Amino Acids. 2013;45(3):463–77. [DOI] [PubMed] [Google Scholar]
46.van Vlies N, Ferdinandusse S, Turkenburg M, Wanders RJ, Vaz FM. PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochim Biophys Acta. 2007;1767(9):1134–42. 10.1016/j.bbabio.2007.07.001 [DOI] [PubMed] [Google Scholar]
47.Peeters A, Baes M. Role of PPARalpha in Hepatic Carbohydrate Metabolism. PPAR Res. 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
48.Kim HI, Ahn YH. Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes. 2004;53 Suppl 1:S60–5. [DOI] [PubMed] [Google Scholar]
49.McCormick DB. Riboflavin In: Erdman JW, Macdonald IA, Zeisel SH, editors. Present Knowledge in Nutrition. 10 ed: Wiley-Blackwell; 2012. 10.1016/j.nut.2011.07.010 [DOI] [Google Scholar]
50.Loo Y, Shin M, Yamashita Y, Ishigami M, Sasaki M, Sano K, et al. Effect of feeding clofibrate-containing diet on the hepatic NAD+ level in rats. J Nutr Sci Vitaminol (Tokyo). 1995;41(3):341–7. 10.3177/jnsv.41.341 [DOI] [PubMed] [Google Scholar]
51.Ringeissen S, Connor SC, Brown HR, Sweatman BC, Hodson MP, Kenny SP, et al. Potential urinary and plasma biomarkers of peroxisome proliferation in the rat: identification of N-methylnicotinamide and N-methyl-4-pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography. Biomarkers. 2003;8(3–4):240–71. 10.1080/1354750031000149124 [DOI] [PubMed] [Google Scholar]
52.Stavrum AK, Heiland I, Schuster S, Puntervoll P, Ziegler M. Model of tryptophan metabolism, readily scalable using tissue-specific gene expression data. J Biol Chem. 2013;288(48):34555–66. 10.1074/jbc.M113.474908 [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Shin M, Ohnishi M, Iguchi S, Sano K, Umezawa C. Peroxisome-proliferator regulates key enzymes of the tryptophan-NAD+ pathway. Toxicol Appl Pharmacol. 1999;158(1):71–80. 10.1006/taap.1999.8683 [DOI] [PubMed] [Google Scholar]
54.Shin M, Kim I, Inoue Y, Kimura S, Gonzalez FJ. Regulation of mouse hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme in the tryptophan-nicotinamide adenine dinucleotide pathway, by hepatocyte nuclear factor 4alpha and peroxisome proliferator-activated receptor alpha. Mol Pharmacol. 2006;70(4):1281–90. 10.1124/mol.106.026294 [DOI] [PubMed] [Google Scholar]
55.Ueland PM, McCann A, Midttun O, Ulvik A. Inflammation, vitamin B6 and related pathways. Mol Aspects Med. 2017;53:10–27. 10.1016/j.mam.2016.08.001 [DOI] [PubMed] [Google Scholar]
56.Ueland PM, Ulvik A, Rios-Avila L, Midttun O, Gregory JF. Direct and functional biomarkers of vitamin B6 status. Annu Rev Nutr. 2015;35:33–70. 10.1146/annurev-nutr-071714-034330 [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, et al. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord. 2009;9(10). [DOI] [PMC free article] [PubMed] [Google Scholar]
58.di Salvo ML, Contestabile R, Safo MK. Vitamin B(6) salvage enzymes: mechanism, structure and regulation. Biochim Biophys Acta. 2011;1814(11):1597–608. 10.1016/j.bbapap.2010.12.006 [DOI] [PubMed] [Google Scholar]
59.Hannibal L, Lysne V, Bjorke-Monsen AL, Behringer S, Grunert SC, Spiekerkoetter U, et al. Biomarkers and Algorithms for the Diagnosis of Vitamin B12 Deficiency. Front Mol Biosci. 2016;3:27 10.3389/fmolb.2016.00027 [DOI] [PMC free article] [PubMed] [Google Scholar]
60.Molloy AM, Pangilinan F, Mills JL, Shane B, O'Neill MB, McGaughey DM, et al. A Common Polymorphism in HIBCH Influences Methylmalonic Acid Concentrations in Blood Independently of Cobalamin. Am J Hum Genet. 2016;98(5):869–82. 10.1016/j.ajhg.2016.03.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
61.Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002 10.1621/nrs.08002 [DOI] [PMC free article] [PubMed] [Google Scholar]
62.Kobayashi R, Murakami T, Obayashi M, Nakai N, Jaskiewicz J, Fujiwara Y, et al. Clofibric acid stimulates branched-chain amino acid catabolism by three mechanisms. Arch Biochem Biophys. 2002;407(2):231–40. 10.1016/s0003-9861(02)00472-1 [DOI] [PubMed] [Google Scholar]
63.Hannibal L, DiBello PM, Jacobsen DW. Proteomics of vitamin B12 processing. Clin Chem Lab Med. 2013;51(3):477–88. 10.1515/cclm-2012-0568 [DOI] [PubMed] [Google Scholar]
64.Mosharov E, Cranford MR, Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry. 2000;39(42):13005–11. 10.1021/bi001088w [DOI] [PubMed] [Google Scholar]
65.Fang L, Zhang M, Li Y, Liu Y, Cui Q, Wang N. PPARgene: A Database of Experimentally Verified and Computationally Predicted PPAR Target Genes. PPAR Res. 2016;2016:6042162 10.1155/2016/6042162 [DOI] [PMC free article] [PubMed] [Google Scholar]
66.Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412 10.1371/journal.pbio.1000412 [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0226069.r001

Decision Letter 0

Nick Ashton

8 Oct 2019

PONE-D-19-18869

Short-term treatment with a peroxisome proliferator-activated receptor α agonist influences plasma one-carbon metabolites and B-vitamin status in rats

PLOS ONE

Dear Mr. Lysne,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewer finds your study to be of interest; however they raise a number of issues which you should consider in revising your manuscript. In particular, please respond to the comment regarding hepatic PPARγ activation in your previous publication (ref 36) as it relates to the current study. The reviewer also requests that you perform some additional analyses to avoid duplication and build upon results presented in your previous publication.

We would appreciate receiving your revised manuscript by Nov 22 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Nick Ashton, PhD

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please complete and submit a copy of the ARRIVE Guidelines checklist, a document that aims to improve experimental reporting and reproducibility of animal studies for purposes of post-publication data analysis and reproducibility: https://www.nc3rs.org.uk/arrive-guidelines. Please include your completed checklist as a Supporting Information file. Note that if your paper is accepted for publication, this checklist will be published as part of your article.

3. Please review your funding statement as per our policy on disclosure of funding sources (http://journals.plos.org/plosone/s/disclosure-of-funding-sources) .

4. We note that one or more of the authors are employed by a commercial company: Bevital AS.

a) Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

b) Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The results showed in the manuscript give some significent explain of the effect of PPARα and PPARγ on one-carbon matbolism. However, the paper is unsuitable for publication in its present form. There are some problem and suggestion as followed.

1 Energy intake should be describle more detail.

2 Although the PPARα and PPARγ mRNA expression were anaylazied ( in reference 36 ), there no difference of PPARγ mRNA level between PPARγ and control, if PPARγ was not activated in haptic and adipose tissue, how do you get the conclusion that PPARγ activatoin has rarely accosiated with one carbon matebolism? In fact, according the experiment data showed in reference 36. It seemed that PPARα mRNA expression significantly increased compared with control only in heptaic tissue, howerer, it did not seem the PPARα agonist had significant effect on PPARα expression in adipose tissue.

3 It is not approved to separate the data of PPAR expression from the data of one-carbon matebolism products. Please provide data of wester-blotting or ELISA to certify PPARα and PPARγ expression at higher level under the intervention of agonist in current study, avoiding repetition data in literature 36.

4 The describe of PPARα expression should be showed in discussion in line 91-94.

5 The analysis of genes expresssion of serine-hydroxymethyltransferase, ACMS dehydrogenase , QAPRT, methylmalonyl-CoA mutase are necessary, otherwise, the avalible evidence is not very convincing.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Plos one-review.docx

Click here for additional data file.^{(15.1KB, docx)}

PLoS One. 2019 Dec 5;14(12):e0226069. doi: 10.1371/journal.pone.0226069.r002

Author response to Decision Letter 0

4 Nov 2019

1. Energy intake should be described more detail.

A: We have added a comment on how feed intake was estimated on line 92. Feed intake was higher in the PPARγ-group, and that group also gained slightly more total body weight as compared to the other groups.

2. Although the PPARα and PPARγ mRNA expression were anaylazied ( in reference 36 ), there no difference of PPARγ mRNA level between PPARγ and control, if PPARγ was not activated in haptic and adipose tissue, how do you get the conclusion that PPARγ activatoin has rarely accosiated with one carbon matebolism? In fact, according the experiment data showed in reference 36. It seemed that PPARα mRNA expression significantly increased compared with control only in heptaic tissue, howerer, it did not seem the PPARα agonist had significant effect on PPARα expression in adipose tissue.

A: Activation of PPARs does not necessarily lead to increased PPAR mRNA, so the lack of effect on the gene level should not be interpreted as an indication of lack in activation. When the PPARs are activated, the genetic expression of their target genes are induced. In our previous publication, we demonstrate large increases in the hepatic expression of several PPARα target genes (e.g. Acox1, Cd36, LPL and Hmgcs2) and adipose tissue expression of PPARγ target genes (e.g. Fatp1 and Fabp4) in the respective treatment groups. As the PPAR-activating effect of the agonists used in this experiment are well established, demonstrating this was not a goal in the current experiment. However, we are very confident that the PPARs were activated, as demonstrated by the effect on target genes.

To avoid confusion, we have replaced any reference to PPARα activation with treatment with PPARα-agonist, and PPARγ-activation with treatment with PPARγ-agonist, when discussing the present findings.

3. It is not approved to separate the data of PPAR expression from the data of one-carbon matebolism products. Please provide data of wester-blotting or ELISA to certify PPARα and PPARγ expression at higher level under the intervention of agonist in current study, avoiding repetition data in literature 36.

A: As mentioned, data on PPAR expression would not inform any inference regarding PPAR activation. Also, due to lack of biological material, we are not able to perform additional laboratory analyses from this experiment. We hope the reviewer and editor accept that we are unfortunately not able to provide this data.

We do agree with the reviewer that some indices of PPAR activation should be included in the current manuscript. However, to avoid repetition from the main publication, we have included some results in the text with reference to the original publication (reference 36) on lines 95-99, as well as mentioning this as a limitation in the discussion section.

4. The describe of PPARα expression should be showed in discussion in line 91-94.

A: We have added some data demonstrating PPARα and PPARγ-activation on lines 95-99, with reference to our previous publication.

5. The analysis of genes expresssion of serine-hydroxymethyltransferase, ACMS dehydrogenase , QAPRT, methylmalonyl-CoA mutase are necessary, otherwise, the avalible evidence is not very convincing.

A: We absolutely agree with the reviewer that this information would be very useful to aid the proposed mechanistic explanation. However, this was not included in the original protocol for the experiment, and due to lack of biological material it will unfortunately not be possible to perform additional laboratory analyses.

However, we think our data still holds value, as we show that treatment with PPAR-agonists does influence the circulating metabolites. Although we, based on our data, cannot pinpoint the exact mechanisms, the pronounced effects on these metabolites cannot be ignored. We do think that concordance with previous literature showing an effect on the gene level strengthen our results, although we were not able to measure those enzymes in this specific experiment. We have added a sentence highlighting this limitation in the discussion section.

Attachment

Submitted filename: Response to reviewers.docx

Click here for additional data file.^{(81.9KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0226069.r003

Decision Letter 1

Nick Ashton

20 Nov 2019

Short-term treatment with a peroxisome proliferator-activated receptor α agonist influences plasma one-carbon metabolites and B-vitamin status in rats

PONE-D-19-18869R1

Dear Dr. Lysne,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Nick Ashton, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

PLoS One. doi: 10.1371/journal.pone.0226069.r004

Acceptance letter

Nick Ashton

25 Nov 2019

PONE-D-19-18869R1

Short-term treatment with a peroxisome proliferator-activated receptor α agonist influences plasma one-carbon metabolites and B-vitamin status in rats

Dear Dr. Lysne:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Nick Ashton

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Arrive Checklist

(PDF)

Click here for additional data file.^{(1MB, pdf)}

S1 Fig. Individual metabolite concentrations with overlaying box plots.

(TIF)

Click here for additional data file.^{(2.7MB, tif)}

S2 Fig. Cage mean metabolite concentrations with overlaying box plots.

(TIF)

Click here for additional data file.^{(2.5MB, tif)}

S1 Dataset. Raw data on metabolite concentrations.

(XLSX)

Click here for additional data file.^{(12.5KB, xlsx)}

Attachment

Submitted filename: Plos one-review.docx

Click here for additional data file.^{(15.1KB, docx)}

Attachment

Submitted filename: Response to reviewers.docx

Click here for additional data file.^{(81.9KB, docx)}

Data Availability Statement

All relevant data are within the manuscript and its Supporting Information files.

[pone.0226069.ref001] 1.Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1(5):228–37. 10.1016/0955-2863(90)90070-2 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref002] 2.Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217–46. 10.1146/annurev.nutr.19.1.217 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref003] 3.Svingen GF, Schartum-Hansen H, Pedersen ER, Ueland PM, Tell GS, Mellgren G, et al. Prospective Associations of Systemic and Urinary Choline Metabolites with Incident Type 2 Diabetes. Clin Chem. 2016;62(5):755–65. 10.1373/clinchem.2015.250761 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref004] 4.Schartum-Hansen H, Pedersen ER, Svingen GF, Ueland PM, Seifert R, Ebbing M, et al. Plasma choline, smoking, and long-term prognosis in patients with stable angina pectoris. European journal of preventive cardiology. 2014;22(5):606–14. 10.1177/2047487314524867 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref005] 5.Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis. 2011;34(1):3–15. 10.1007/s10545-010-9088-4 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref006] 6.Schartum-Hansen H, Ueland PM, Pedersen ER, Meyer K, Ebbing M, Bleie O, et al. Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients. PLoS One. 2013;8(8):e69454 10.1371/journal.pone.0069454 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref007] 7.Lever M, George PM, Elmslie JL, Atkinson W, Slow S, Molyneux SL, et al. Betaine and secondary events in an acute coronary syndrome cohort. PLoS One. 2012;7(5):e37883 10.1371/journal.pone.0037883 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref008] 8.Svingen GF, Schartum-Hansen H, Ueland PM, Pedersen ER, Seifert R, Ebbing M, et al. Elevated plasma dimethylglycine is a risk marker of mortality in patients with coronary heart disease. European journal of preventive cardiology. 2014;22(6):743–52. 10.1177/2047487314529351 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref009] 9.Oyen J, Svingen GF, Gjesdal CG, Tell GS, Ueland PM, Lysne V, et al. Plasma dimethylglycine, nicotine exposure and risk of low bone mineral density and hip fracture: the Hordaland Health Study. Osteoporos Int. 2015;26(5):1573–83. 10.1007/s00198-015-3030-4 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref010] 10.Svingen GF, Ueland PM, Pedersen EK, Schartum-Hansen H, Seifert R, Ebbing M, et al. Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol. 2013;33(8):2041–8. 10.1161/ATVBAHA.113.301714 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref011] 11.Koutros S, Meyer TE, Fox SD, Issaq HJ, Veenstra TD, Huang WY, et al. Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis. 2013;34(10):2281–5. 10.1093/carcin/bgt176 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref012] 12.de Vogel S, Ulvik A, Meyer K, Ueland PM, Nygard O, Vollset SE, et al. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer—a large nested case-control study within the JANUS cohort in Norway. Int J Cancer. 2014;134(1):197–206. 10.1002/ijc.28347 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref013] 13.Ding Y, Svingen GF, Pedersen ER, Gregory JF, Ueland PM, Tell GS, et al. Plasma Glycine and Risk of Acute Myocardial Infarction in Patients With Suspected Stable Angina Pectoris. J Am Heart Assoc. 2015;5(1):e002621 10.1161/JAHA.115.002621 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref014] 14.Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13(8):572–83. 10.1038/nrc3557 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref015] 15.Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39(4):191–8. 10.1016/j.tibs.2014.02.004 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref016] 16.Rakhshandehroo M, Knoch B, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref017] 17.Contreras AV, Torres N, Tovar AR. PPAR-alpha as a key nutritional and environmental sensor for metabolic adaptation. Adv Nutr. 2013;4(4):439–52. 10.3945/an.113.003798 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref018] 18.Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR, Oakes ND. Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. American journal of physiology Endocrinology and metabolism. 2007;292(4):E1157–65. 10.1152/ajpendo.00254.2006 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref019] 19.Rogue A, Renaud MP, Claude N, Guillouzo A, Spire C. Comparative gene expression profiles induced by PPARgamma and PPARalpha/gamma agonists in rat hepatocytes. Toxicol Appl Pharmacol. 2011;254(1):18–31. 10.1016/j.taap.2011.04.005 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref020] 20.Wrzesinski K, I RL, Kulej K, Sprenger RR, Bjorndal B, Christensen BJ, et al. Proteomics identifies molecular networks affected by tetradecylthioacetic acid and fish oil supplemented diets. J Proteomics. 2013;84:61–77. 10.1016/j.jprot.2013.03.027 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref021] 21.Chu R, Lim H, Brumfield L, Liu H, Herring C, Ulintz P, et al. Protein profiling of mouse livers with peroxisome proliferator-activated receptor alpha activation. Mol Cell Biol. 2004;24(14):6288–97. 10.1128/MCB.24.14.6288-6297.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref022] 22.Ntaios G, Savopoulos C, Chatzopoulos S, Mikhailidis D, Hatzitolios A. Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis. 2011;214(1):11–9. 10.1016/j.atherosclerosis.2010.08.045 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref023] 23.Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med. 2005;5(2):124–39. 10.1055/s-2005-872398 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref024] 24.Lever M, McEntyre CJ, George PM, Slow S, Chambers ST, Foucher C. Fenofibrate causes elevation of betaine excretion but not excretion of other osmolytes by healthy adults. J Clin Lipidol. 2014;8(4):433–40. 10.1016/j.jacl.2014.04.001 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref025] 25.Lever M, McEntyre CJ, George PM, Slow S, Elmslie JL, Lunt H, et al. Extreme urinary betaine losses in type 2 diabetes combined with bezafibrate treatment are associated with losses of dimethylglycine and choline but not with increased losses of other osmolytes. Cardiovasc Drugs Ther. 2014;28(5):459–68. 10.1007/s10557-014-6542-9 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref026] 26.Lever M, George PM, Slow S, Elmslie JL, Scott RS, Richards AM, et al. Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc Drugs Ther. 2009;23(5):395–401. 10.1007/s10557-009-6188-1 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref027] 27.Lever M, George PM, Atkinson W, Molyneux SL, Elmslie JL, Slow S, et al. Plasma lipids and betaine are related in an acute coronary syndrome cohort. PLoS One. 2011;6(7):e21666 10.1371/journal.pone.0021666 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref028] 28.Lysne V, Strand E, Svingen GF, Bjorndal B, Pedersen ER, Midttun O, et al. Peroxisome Proliferator-Activated Receptor Activation is Associated with Altered Plasma One-Carbon Metabolites and B-Vitamin Status in Rats. Nutrients. 2016;8(1). [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref029] 29.Ericsson A, Turner N, Hansson GI, Wallenius K, Oakes ND. Pharmacological PPARalpha activation markedly alters plasma turnover of the amino acids glycine, serine and arginine in the rat. PLoS One. 2014;9(12):e113328 10.1371/journal.pone.0113328 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref030] 30.Lu Y, Boekschoten MV, Wopereis S, Muller M, Kersten S. Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice. Physiol Genomics. 2011;43(23):1307–18. 10.1152/physiolgenomics.00100.2011 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref031] 31.Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol. 2009;37(4):521–35. 10.1177/0192623309336152 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref032] 32.Mayer O Jr., Simon J, Holubec L, Pikner R, Subrt I. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur J Clin Pharmacol. 2003;59(5–6):367–71. 10.1007/s00228-003-0616-0 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref033] 33.Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999;354(9174):219–20. 10.1016/S0140-6736(99)02153-4 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref034] 34.Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ. Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol. 2007;21(9):2136–51. 10.1210/me.2007-0150 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref035] 35.Delaney J, Hodson MP, Thakkar H, Connor SC, Sweatman BC, Kenny SP, et al. Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Arch Toxicol. 2005;79(4):208–23. 10.1007/s00204-004-0625-5 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref036] 36.Strand E, Lysne V, Grinna ML, Bohov P, Svardal A, #xf8, et al. Short-Term Activation of Peroxisome Proliferator-Activated Receptors and Induces Tissue-Specific Effects on Lipid Metabolism and Fatty Acid Composition in Male Wistar Rats. PPAR Research. 2019;2019:12. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref037] 37.Midttun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009;23(9):1371–9. 10.1002/rcm.4013 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref038] 38.Midttun O, Kvalheim G, Ueland PM. High-throughput, low-volume, multianalyte quantification of plasma metabolites related to one-carbon metabolism using HPLC-MS/MS. Anal Bioanal Chem. 2013;405(6):2009–17. 10.1007/s00216-012-6602-6 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref039] 39.Kelleher BP, Broin SD. Microbiological assay for vitamin B12 performed in 96-well microtitre plates. J Clin Pathol. 1991;44(7):592–5. 10.1136/jcp.44.7.592 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref040] 40.Midttun O, McCann A, Aarseth O, Krokeide M, Kvalheim G, Meyer K, et al. Combined Measurement of 6 Fat-Soluble Vitamins and 26 Water-Soluble Functional Vitamin Markers and Amino Acids in 50 muL of Serum or Plasma by High-Throughput Mass Spectrometry. Anal Chem. 2016;88(21):10427–36. 10.1021/acs.analchem.6b02325 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref041] 41.Cohen J. A power primer. Psychol Bull. 1992;112(1):155–9. 10.1037//0033-2909.112.1.155 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref042] 42.Team RC. R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing, Vienna, Austria; 2018. [Google Scholar]

[pone.0226069.ref043] 43.Bjorndal B, Brattelid T, Strand E, Vigerust NF, Svingen GF, Svardal A, et al. Fish oil and the pan-PPAR agonist tetradecylthioacetic acid affect the amino acid and carnitine metabolism in rats. PLoS One. 2013;8(6):e66926 10.1371/journal.pone.0066926 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref044] 44.Bremer J. Carnitine—metabolism and functions. Physiol Rev. 1983;63(4):1420–80. 10.1152/physrev.1983.63.4.1420 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref045] 45.Wang W, Wu Z, Dai Z, Yang Y, Wang J, Wu G. Glycine metabolism in animals and humans: implications for nutrition and health. J Amino Acids. 2013;45(3):463–77. [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref046] 46.van Vlies N, Ferdinandusse S, Turkenburg M, Wanders RJ, Vaz FM. PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochim Biophys Acta. 2007;1767(9):1134–42. 10.1016/j.bbabio.2007.07.001 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref047] 47.Peeters A, Baes M. Role of PPARalpha in Hepatic Carbohydrate Metabolism. PPAR Res. 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref048] 48.Kim HI, Ahn YH. Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes. 2004;53 Suppl 1:S60–5. [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref049] 49.McCormick DB. Riboflavin In: Erdman JW, Macdonald IA, Zeisel SH, editors. Present Knowledge in Nutrition. 10 ed: Wiley-Blackwell; 2012. 10.1016/j.nut.2011.07.010 [DOI] [Google Scholar]

[pone.0226069.ref050] 50.Loo Y, Shin M, Yamashita Y, Ishigami M, Sasaki M, Sano K, et al. Effect of feeding clofibrate-containing diet on the hepatic NAD+ level in rats. J Nutr Sci Vitaminol (Tokyo). 1995;41(3):341–7. 10.3177/jnsv.41.341 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref051] 51.Ringeissen S, Connor SC, Brown HR, Sweatman BC, Hodson MP, Kenny SP, et al. Potential urinary and plasma biomarkers of peroxisome proliferation in the rat: identification of N-methylnicotinamide and N-methyl-4-pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography. Biomarkers. 2003;8(3–4):240–71. 10.1080/1354750031000149124 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref052] 52.Stavrum AK, Heiland I, Schuster S, Puntervoll P, Ziegler M. Model of tryptophan metabolism, readily scalable using tissue-specific gene expression data. J Biol Chem. 2013;288(48):34555–66. 10.1074/jbc.M113.474908 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref053] 53.Shin M, Ohnishi M, Iguchi S, Sano K, Umezawa C. Peroxisome-proliferator regulates key enzymes of the tryptophan-NAD+ pathway. Toxicol Appl Pharmacol. 1999;158(1):71–80. 10.1006/taap.1999.8683 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref054] 54.Shin M, Kim I, Inoue Y, Kimura S, Gonzalez FJ. Regulation of mouse hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme in the tryptophan-nicotinamide adenine dinucleotide pathway, by hepatocyte nuclear factor 4alpha and peroxisome proliferator-activated receptor alpha. Mol Pharmacol. 2006;70(4):1281–90. 10.1124/mol.106.026294 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref055] 55.Ueland PM, McCann A, Midttun O, Ulvik A. Inflammation, vitamin B6 and related pathways. Mol Aspects Med. 2017;53:10–27. 10.1016/j.mam.2016.08.001 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref056] 56.Ueland PM, Ulvik A, Rios-Avila L, Midttun O, Gregory JF. Direct and functional biomarkers of vitamin B6 status. Annu Rev Nutr. 2015;35:33–70. 10.1146/annurev-nutr-071714-034330 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref057] 57.Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, et al. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord. 2009;9(10). [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref058] 58.di Salvo ML, Contestabile R, Safo MK. Vitamin B(6) salvage enzymes: mechanism, structure and regulation. Biochim Biophys Acta. 2011;1814(11):1597–608. 10.1016/j.bbapap.2010.12.006 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref059] 59.Hannibal L, Lysne V, Bjorke-Monsen AL, Behringer S, Grunert SC, Spiekerkoetter U, et al. Biomarkers and Algorithms for the Diagnosis of Vitamin B12 Deficiency. Front Mol Biosci. 2016;3:27 10.3389/fmolb.2016.00027 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref060] 60.Molloy AM, Pangilinan F, Mills JL, Shane B, O'Neill MB, McGaughey DM, et al. A Common Polymorphism in HIBCH Influences Methylmalonic Acid Concentrations in Blood Independently of Cobalamin. Am J Hum Genet. 2016;98(5):869–82. 10.1016/j.ajhg.2016.03.005 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref061] 61.Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002 10.1621/nrs.08002 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref062] 62.Kobayashi R, Murakami T, Obayashi M, Nakai N, Jaskiewicz J, Fujiwara Y, et al. Clofibric acid stimulates branched-chain amino acid catabolism by three mechanisms. Arch Biochem Biophys. 2002;407(2):231–40. 10.1016/s0003-9861(02)00472-1 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref063] 63.Hannibal L, DiBello PM, Jacobsen DW. Proteomics of vitamin B12 processing. Clin Chem Lab Med. 2013;51(3):477–88. 10.1515/cclm-2012-0568 [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref064] 64.Mosharov E, Cranford MR, Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry. 2000;39(42):13005–11. 10.1021/bi001088w [DOI] [PubMed] [Google Scholar]

[pone.0226069.ref065] 65.Fang L, Zhang M, Li Y, Liu Y, Cui Q, Wang N. PPARgene: A Database of Experimentally Verified and Computationally Predicted PPAR Target Genes. PPAR Res. 2016;2016:6042162 10.1155/2016/6042162 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0226069.ref066] 66.Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412 10.1371/journal.pbio.1000412 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Short-term treatment with a peroxisome proliferator-activated receptor α agonist influences plasma one-carbon metabolites and B-vitamin status in rats

Vegard Lysne

Bodil Bjørndal

Mari Lausund Grinna

Øivind Midttun

Per Magne Ueland

Rolf Kristian Berge

Jutta Dierkes

Ottar Nygård

Elin Strand

Roles

Abstract

Introduction

Methods

Results

Conclusion

Introduction

Fig 1. Overview of metabolic pathways discussed.

Materials and methods

Animals and study design

Ethics statement

Biochemical analyses

Statistical analyses and presentation of data

Results

Fig 2. Biomarker concentrations, given as geometric mean (geometric standard deviations).

Discussion

Strengths and limitations

Conclusion

Supporting information

Acknowledgments

Abbreviations

Data Availability

Funding Statement

References

Decision Letter 0

Nick Ashton

Roles

Author response to Decision Letter 0

Decision Letter 1

Nick Ashton

Roles

Acceptance letter

Nick Ashton

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases